Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2012, Pages

  Cacciatore, Ivana ^a   Baldassarre, Leonardo ^a   Fornasari, Erika ^a   Mollica, Adriano ^a   Pinnen, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER'S DISEASE; BRAIN CELLS; CENTRAL NERVOUS SYSTEMS; DELIVERY SYSTEMS; GLUTATHIONES; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE DAMAGE; PARKINSON'S DISEASE; POOR STABILITY; TECHNOLOGY-BASED; THERAPEUTIC AGENTS;

BIOCHEMISTRY; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; DRUG DELIVERY; FREE RADICALS; PATHOLOGY; RNA;

NEURODEGENERATIVE DISEASES;

DNA; FREE RADICAL; GLUTATHIONE; GLUTATHIONE DERIVATIVE; LIPID; PROTEIN; RNA; DRUG CARRIER; NANOPARTICLE;

ALZHEIMER DISEASE; APOPTOSIS; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GLUTATHIONE METABOLISM; HUMAN; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; BRAIN; CHEMISTRY; METABOLISM; PATHOLOGY;

BRAIN; DRUG CARRIERS; GLUTATHIONE; HUMANS; NANOPARTICLES; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 84863644562     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2012/240146     Document Type: Review

References (100)

1. Jellinker K. A., General aspects of neurodegeneration Journal of Neural Transmission 2003 65 101 144
2. Jellinger K. A., Basic mechanisms of neurodegeneration: a critical update Journal of Cellular and Molecular Medicine 2010 14 3 457 487
3. Valko M., Leibfritz D., Moncol J., Cronin M. T. D., Mazur M., Telser J., Free radicals and antioxidants in normal physiological functions and human disease International Journal of Biochemistry and Cell Biology 2007 39 1 44 84 (Pubitemid 44566469)
4. Melo A., Monteiro L., Lima R. M. F., de Oliveira D. M., de Cerqueira M. D., El-Bacha R. S., Oxidative stress in neurodegenerative diseases: mechanism and therapeutic perspectives Oxidative Medicine and Cellular Longevity 2011 2011 14
5. Markesbery W. R., The role of oxidative stress in Alzheimer disease Archives of Neurology 1999 56 12 1449 1452
6. Sayre L. M., Smith M. A., Perry G., Chemistry and biochemistry of oxidative stress in neurodegenerative disease Current Medicinal Chemistry 2001 8 7 721 738 (Pubitemid 32427903)
7. Coyle J. T., Puttfarcken P., Oxidative stress, glutamate, and neurodegenerative disorders Science 1993 262 5134 689 695 (Pubitemid 23350687)
8. Jenner P., Oxidative stress in Parkinson's disease Annals of Neurology 2003 53 supplement 3 S26 S38
9. Polidori M. C., Griffiths H. R., Mariani E., Mecocci P., Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease Amino Acids 2007 32 4 553 559 (Pubitemid 46790937)
10. Moreira P. I., Honda K., Quan L., Aliev G., Oliveira C. R., Santos M. S., Zhu X., Smith M. A., Perry G., Alzheimer's disease and oxidative stress: the old problem remains unsolved Current Medicinal Chemistry 2005 5 1 51 62 (Pubitemid 40392917)
11. Farooqui T., Farooqui A. A., Aging: an important factor for the pathogenesis of neurodegenerative diseases Mechanisms of Ageing and Development 2009 130 4 203 215
12. Fahn S., Cohen G., The oxidant stress hypothesis in Parkinson's disease: evidence supporting it Annals of Neurology 1992 32 6 804 812
13. Offen D., Gorodin S., Melamed E., Hanania J., Malik Z., Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease Neuroscience Letters 1999 260 2 101 104 (Pubitemid 29066875)
14. Schulz J. B., Lindenau J., Seyfried J., Dichgans J., Glutathione, oxidative stress and neurodegeneration European Journal of Biochemistry 2000 267 16 4904 4911 (Pubitemid 30641286)
15. Bains J. S., Shaw C. A., Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death Brain Research Reviews 1997 25 3 335 358 (Pubitemid 28071452)
16. Lee M., Cho T., Jantaratnotai N., Wang Y. T., McGeer E., McGeer P. L., Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases The FASEB Journal 2010 24 7 2533 2545
17. Pearce R. K. B., Owen A., Daniel S., Jenner P., Marsden C. D., Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease Journal of Neural Transmission 1997 104 6-7 661 677 (Pubitemid 27474680)
18. Sian J., Dexter D. T., Lees A. J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C. D., Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Annals of Neurology 1994 36 3 348 355 (Pubitemid 24280055)
19. Damier P., Hirsch E. C., Zhang P., Agid Y., Javoy-Agid F., Glutathione peroxidase, glial cells and Parkinson's disease Neuroscience 1993 52 1 1 6 (Pubitemid 23026600)
20. Garrido M., Tereshchenko Y., Zhevtsova Z., Taschenberger G., Bhr M., Kgler S., Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons Acta Neuropathologica 2011 121 4 475 485
21. Albers D. S., Beal M. F., Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease Journal of Neural Transmission 2000 59 133 154 (Pubitemid 30479414)
22. Jenner P., Oxidative mechanisms in nigral cell death in Parkinson's disease Movement Disorders 1998 13 1 24 34
23. Spencer J. P. E., Jenner P., Daniel S. E., Lees A. J., Marsden D. C., Halliwell B., Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species Journal of Neurochemistry 1998 71 5 2112 2122 (Pubitemid 28491568)
24. Andersen J. K., Mo J. Q., Horn D. G., Lee F. Y., Harnish P., Hamill R. W., McNeill T. H., Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons Journal of Neurochemistry 1996 67 5 2164 2171 (Pubitemid 26349695)
25. Lin M. T., Beal M. F., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases Nature 2006 443 7113 787 795 (Pubitemid 44622683)
26. Chinta S. J., Andersen J. K., Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease Free Radical Biology and Medicine 2006 41 9 1442 1448 (Pubitemid 44466728)
27. Chinta S. J., Kumar M. J., Hsu M., Rajagopalan S., Kaur D., Rane A., Nicholls D. G., Choi J., Andersen J. K., Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration Journal of Neuroscience 2007 27 51 13997 14006 (Pubitemid 351377875)
28. Lau L. F., Brodney M. A., Therapeutic approaches for the treatment of Alzheimers disease: an overview Topics in Medicinal Chemistry 2008 2 1 24
29. Varadarajan S., Yatin S., Aksenova M., Butterfield D. A., Review: Alzheimer's amyloid -peptide-associated free radical oxidative stress and neurotoxicity Journal of Structural Biology 2000 130 2-3 184 208
30. Maltsev A. V., Bystryak S., Galzitskaya O. V., The role of -amyloid peptide in neurodegenerative diseases Ageing Research Reviews 2011 10 440 452
31. Gu M., Owen A. D., Toffa S. E. K., Cooper J. M., Dexter D. T., Jenner P., Marsden C. D., Schapira A. H. V., Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases Journal of the Neurological Sciences 1998 158 1 24 29 (Pubitemid 28277530)
32. Liu H., Harrell L. E., Shenvi S., Hagen T., Liu R. M., Gender differences in glutathione metabolism in Alzheimer's disease Journal of Neuroscience Research 2005 79 6 861 867 (Pubitemid 40476510)
33. Adams J. D., Klaidman L. K., Odunze I. N., Shen H. C., Miller C. A., Alzheimer's and Parkinson's disease: brain levels of glutathione, glutathione disulfide, and vitamin E Molecular and Chemical Neuropathology 1991 14 3 213 226
34. Perry T. L., Yong V. W., Bergeron C., Hansen S., Jones K., Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimers disease Annals of Neurology 2005 21 4 331 336
35. Mark R. J., Lovell M. A., Markesbery W. R., Uchida K., Mattson M. P., A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid -peptide Journal of Neurochemistry 1997 68 1 255 264 (Pubitemid 26427315)
36. Butterfield D. A., Pocernich C. B., Drake J., Elevated glutathione as a therapeutic strategy in Alzheimer's disease Drug Development Research 2002 56 3 428 437 (Pubitemid 35168319)
37. Hammond C. L., Lee T. K., Ballatori N., Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes Journal of Hepatology 2001 34 6 946 954 (Pubitemid 32595199)
38. Ghosh N., Ghosh R., Mandal S. C., Antioxidant protection: a promising therapeutic intervention in neurodegenerative disease Free Radical Research 2011 45 8 888 905
39. di Matteo V., Esposito E., Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis Current Drug Targets, CNS Neurological Disorders 2003 2 2 95 107
40. Cacciatore I., Cornacchia C., Baldassarre L., Fornasari E., Mollica A., Stefanucci A., Pinnen F., GPE and GPE analogues as promising neuroprotective agents Mini Reviews in Medicinal Chemistry 2012 12 1 13 23
41. Cornacchia C., Cacciatore I., Baldassarre L., Mollica A., Feliciani F., Pinnen F., 2,5-Diketopiperazines as neuroprotective agents Mini Reviews in Medicinal Chemistry 2012 12 2 12
42. Moosmann B., Behl C., Antioxidants as treatment for neurodegenerative disorders Expert Opinion on Investigational Drugs 2002 11 10 1407 1435 (Pubitemid 35174938)
43. Dringen R., Metabolism and functions of glutathione in brain Progress in Neurobiology 2000 62 6 649 671 (Pubitemid 30407139)
44. Dringen R., Hirrlinger J., Glutathione pathways in the brain Biological Chemistry 2003 384 4 505 516 (Pubitemid 36609167)
45. Bains J. S., Shaw C. A., Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death Brain Research Reviews 1997 25 3 335 358 (Pubitemid 28071452)
46. Townsend D. M., Tew K. D., Tapiero H., The importance of glutathione in human disease Biomedicine and Pharmacotherapy 2003 57 3 145 155 (Pubitemid 36740460)
47. Ballatori N., Krance S. M., Notenboom S., Shi S., Tieu K., Hammond C. L., Glutathione dysregulation and the etiology and progression of human diseases Biological Chemistry 2009 390 3 191 214
48. Martin H. L., Teismann P., Glutathionea review on its role and significance in Parkinson's dysregulation and the etiology and progression of human diseases The FASEB Journal 2009 23 3263 3272
49. Guidi I., Galimberti D., Lonati S., Novembrino C., Bamonti F., Tiriticco M., Fenoglio C., Venturelli E., Baron P., Bresolin N., Scarpini E., Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease Neurobiology of Aging 2006 27 2 262 269 (Pubitemid 43038550)
50. Dumont M., Beal M. F., Neuroprotective strategies involving ROS in Alzheimer disease Free Radical Biology and Medicine 2011 51 1014 1026
51. Mcmanus M. J., Murphy M. P., Franklin J. L., The mitochondria-targeted antioxidant mitoq prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease The Journal of Neuroscience 2011 31 15703 15715
52. Beckman J. S., Estévez A. G., Crow J. P., Barbeito L., Superoxide dismutase and the death of motoneurons in ALS Trends in Neurosciences 2001 24 supplement 11 S15 S20
53. Vargas M. R., Johnson D. A., Johnson J. A., Decreased glutathione accelerates neurologiCal deficit and mitochondrial pathology in familial ALS-linked hSOD1G93A mice model Neurobiology of Disease 2011 43 3 543 551
54. Behl C., Moosmann B., Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach Free Radical Biology and Medicine 2002 33 2 182 191 (Pubitemid 34775190)
55. Zeevalk G. D., Manzino L., Sonsalla P. K., Bernard L. P., Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease Experimental Neurology 2007 203 2 512 520 (Pubitemid 46149596)
56. Cacciatore I., Cornacchia C., Pinnen F., Mollica A., di Stefano A., Prodrug approach for increasing cellular glutathione levels Molecules 2010 15 3 1242 1264
57. Cacciatore I., Cocco A., Costa M., Fontana M., Lucente G., Pecci L., Pinnen F., Biochemical properties of new synthetic carnosine analogues containing the residue of 2,3-diaminopropionic acid: the effect of N-acetylation Amino Acids 2005 28 1 77 83 (Pubitemid 40385398)
58. Brunetti L., Cacciatore I., di Stefano A., Dupr S., Giorgi A., Luisi G., Michelotto B., Orlando G., Pinnen F., Recinella L., Sozio P., Spirito A., Synthesis and biological evaluation of a novel pyroglutamyl-modified TRH analogue Farmaco 2002 57 6 479 486 (Pubitemid 34603780)
59. Denora N., Trapani A., Laquintana V., Lopedota A., Trapani G., Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain Current Topics in Medicinal Chemistry 2009 9 2 182 196
60. Cacciatore I., di Stefano A., Luisi G., Pinnen F., Sozio P., Transition state isosteres of the -glutamyl peptide bond hydrolysis: synthesis and characterization of the (CH 2 NH) pseudopeptide analogue of glutathione Journal of Peptide Science 2004 10 2 109 114 (Pubitemid 38248022)
61. Cacciatore I., Caccuri A. M., di Stefano A., Luisi G., Nalli M., Pinnen F., Ricci G., Sozio P., Synthesis and activity of novel glutathione analogues containing an urethane backbone linkage Farmaco 2003 58 9 787 793 (Pubitemid 37122649)
62. Cacciatore I., Caccuri A. M., Cocco A., De Maria F., Di Stefano A., Luisi G., Pinnen F., Ricci G., Sozio P., Turella P., Potent isozyme-selective inhibition of human glutathione S-transferase A1-1 by a novel glutathione S-conjugate Amino Acids 2005 29 3 255 261 (Pubitemid 41752088)
63. Das N., Dhanawat M., Dash B., Nagarwal R. C., Shrivastava S. K., Codrug: an efficient approach for drug optimization European Journal of Pharmaceutical Sciences 2010 41 5 571 588
64. Decker M., Hybrid molecules incorporating natural products: applications in cancer therapy, neurodegenerative disorders and beyond Current Medicinal Chemistry 2011 18 10 1464 1475
65. Minelli A., Conte C., Cacciatore I., Cornacchia C., Pinnen F., Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model. Amino Acids. In press
66. Sozio P., Iannitelli A., Cerasa L. S., Cacciatore I., Cornacchia C., Giorgioni G., Ricciutelli M., Nasuti C., Cantalamessa F., Di Stefano A., New L-dopa codrugs as potential antiparkinson agents Archiv der Pharmazie 2008 341 7 412 417
67. Malakoutikhah M., Teixid M., Giralt E., Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries Journal of Medicinal Chemistry 2008 51 16 4881 4889
68. Kannan R., Kuhlenkamp J. F., Jeandidier E., Trinh H., Ookhtens M., Kaplowitz N., Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat Journal of Clinical Investigation 1990 85 6 2009 2013 (Pubitemid 20192980)
69. Pinnen F., Cacciatore I., Cornacchia C., Sozio P., Iannitelli A., Costa M., Pecci L., Nasuti C., Cantalamessa F., Di Stefano A., Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties Journal of Medicinal Chemistry 2007 50 10 2506 2515 (Pubitemid 46799262)
70. More S. S., Vince R., Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs Journal of Medicinal Chemistry 2008 51 15 4581 4588
71. Bickel U., Kang Y. S., Pardridge W. M., In vivo cleavability of a disulfide-based chimeric opioid peptide in rat brain Bioconjugate Chemistry 1995 6 2 211 218
72. Pinnen F., Cacciatore I., Cornacchia C., Mollica A., Sozio P., Cerasa L. S., Iannitelli A., Fontana A., Nasuti C., Di Stefano A., CNS delivery of l-dopa by a new hybrid glutathione-methionine peptidomimetic prodrug Amino Acids 2012 42 1 261 269
73. Ehrlich K., Viirlaid S., Mahlapuu R., Saar K., Kullisaar T., Zilmer M., Langel., Soomets U., Design, synthesis and properties of novel powerful antioxidants, glutathione analogues Free Radical Research 2007 41 7 779 787 (Pubitemid 46995259)
74. Ehrlich K., Ida K., Mahlapuu R., Kairane C., Oit I., Zilmer M., Soomets U., Characterization of UPF peptides, members of the glutathione analogues library, on the basis of their effects on oxidative stress-related enzymes Free Radical Research 2009 43 6 572 580
75. Pder P., Zilmer M., Starkopf J., Kals J., Talonpoika A., Pulges A., Langel U., Kullisaar T., Viirlaid S., Mahlapuu R., Zarkovski A., Arend A., Soomets U., An antioxidant tetrapeptide UPF1 in rats has a neuroprotective effect in transient global brain ischemia Neuroscience Letters 2004 370 1 45 50 (Pubitemid 39369854)
76. Karelson E., Mahlapuu R., Zilmer M., Soomets U., Bogdanovic N., Langel Possible signaling by glutathione and its novel analogue through potent stimulation of frontocortical G proteins in normal aging and in Alzheimer's disease Annals of the New York Academy of Sciences 2002 973 537 540 (Pubitemid 36125065)
77. Pinnen F., Sozio P., Cacciatore I., Cornacchia C., Mollica A., Iannitelli A., Daurizio E., Cataldi A., Zara S., Nasuti C., Di Stefano A., Ibuprofen and glutathione conjugate as a potential therapeutic agent for treating Alzheimer's disease Archiv der Pharmazie 2011 344 3 139 148
78. Prasad K. N., Cole W. C., Prasad K. C., Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment Journal of the American College of Nutrition 2002 21 6 506 522 (Pubitemid 36026262)
79. Lim G. P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K. H., Frautschy S. A., Cole G. M., Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease Journal of Neuroscience 2000 20 15 5709 5714 (Pubitemid 30636898)
80. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A. L., Citron M., Landreth G., Anti-inflammatory drug therapy alters -amyloid processing and deposition in an animal model of Alzheimer's disease Journal of Neuroscience 2003 23 20 7504 7509 (Pubitemid 37034066)
81. Atmaca G., Antioxidant effects of sulfur-containing amino acids Yonsei Medical Journal 2004 45 5 776 788 (Pubitemid 39545364)
82. Pinnen F., Cacciatore I., Cornacchia C., Sozio P., Cerasa L. S., Iannitelli A., Nasuti C., Cantalamessa F., Sekar D., Gabbianelli R., Falcioni M. L., Di Stefano A., Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson's disease Journal of Medicinal Chemistry 2009 52 2 559 563
83. Offen D., Ziv I., Sternin H., Melamed E., Hochman A., Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease Experimental Neurology 1996 141 1 32 39 (Pubitemid 26317179)
84. Minelli A., Conte C., Prudenzi E., Cacciatore I., Cornacchia C., Taha E., Pinnen F., N-Acetyl-L-Methionyl-L-Dopa-Methyl Ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity Free Radical Biology and Medicine 2010 49 1 31 39
85. Torres J. L., Lozano C., Maher P., Conjugation of catechins with cysteine generates antioxidant compounds with enhanced neuroprotective activity Phytochemistry 2005 66 17 2032 2037 (Pubitemid 41261914)
86. Maher P., Lewerenz J., Lozano C., Torres J. L., A novel approach to enhancing cellular glutathione levels Journal of Neurochemistry 2008 107 3 690 700
87. Sato H., Tamba M., Ishii T., Bannai S., Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins Journal of Biological Chemistry 1999 274 17 11455 11458
88. Steinhubl S. R., Why have antioxidants failed in clinical trials? American Journal of Cardiology 2008 101 supplement 10 S14 S19
89. Ratnam D. V., Ankola D. D., Bhardwaj V., Sahana D. K., Kumar M. N. V. R., Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective Journal of Controlled Release 2006 113 3 189 207 (Pubitemid 43983041)
90. Gilmore J. L., Yi X., Quan L., Kabanov A. V., Novel nanomaterials for clinical neuroscience Journal of NeuroImmune Pharmacology 2008 3 2 83 94
91. Chen C., Han D., Cai C., Tang X., An overview of liposome lyophilization and its future potential Journal of Controlled Release 2010 142 3 299 311
92. Zeevalk G. D., Bernard L. P., Guilford F. T., Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells Neurochemical Research 2010 35 10 1575 1587
93. de Jong W. H., Borm P. J. A., Drug delivery and nanoparticles: applications and hazards International Journal of Nanomedicine 2008 3 2 133 149 (Pubitemid 352042401)
94. Aumelas A., Serrero A., Durand A., Dellacherie E., Leonard M., Nanoparticles of hydrophobically modified dextrans as potential drug carrier systems Colloids and Surfaces B 2007 59 1 74 80 (Pubitemid 47016923)
95. Esmaeili F., Ghahremani M. H., Esmaeili B., Khoshayand M. R., Atyabi F., Dinarvand R., PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution International Journal of Pharmaceutics 2008 349 1-2 249 255 (Pubitemid 350299701)
96. Williams S. R., Lepene B. S., Thatcher C. D., Long T. E., Synthesis and characterization of poly(ethylene glycol)-glutathione conjugate self-assembled nanoparticles for antioxidant delivery Biomacromolecules 2009 10 1 155 161
97. Alcantar N. A., Aydil E. S., Israelachvili J. N., Polyethylene glycol-coated biocompatible surfaces Journal of Biomedical Materials Research 2000 51 3 343 351 (Pubitemid 30452136)
98. Koo S. H., Lee J. S., Kim G. H., Lee H. G., Preparation, characteristics, and stability of glutathione-loaded nanoparticles Journal of Agricultural and Food Chemistry 2011 9 11264 11269
99. Agnihotri S. A., Mallikarjuna N. N., Aminabhavi T. M., Recent advances on chitosan-based micro- and nanoparticles in drug delivery Journal of Controlled Release 2004 100 1 5 28 (Pubitemid 39445982)
100. Takeuchi H., Yamamoto H., Kawashima Y., Mucoadhesive nanoparticulate systems for peptide drug delivery Advanced Drug Delivery Reviews 2001 47 1 39 54 (Pubitemid 32209231)